The Top 5 Biosimilars Articles for the Week of April 13

Here are the top 5 biosimilars articles for the week of April 13, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of April 13, 2020.

Number 5: A comparison of the global guidelines shows that the WHO guidance that has impacted the largest patient population is filled with scientific misconceptions, leading to lack of trust in the safety and efficacy of biosimilars developed under this guidance.

Number 4: Oncologist and hematologist, Lee S. Schwartzberg, MD, FACP, describes some important considerations for using biosimilars in clinical practice.

Number 3: With positive phase 1 study results and a manufacturing process that may cut costs significantly, BiosanaPharma hopes its omalizumab biosimilar candidate will have an edge on the worldwide market.

Number 2: NeuClone said phase 1 patient monitoring and blood sampling has been completed for its ustekinumab biosimilar candidate, which is targeted at the $6.6 billion in annual revenue earned by Stelara, a product by Janssen Pharmaceutical Companies.

Number 1: The FDA’s new focus on coronavirus disease 2019 (COVID-19) and the quarantines imposed on much of the developed world have pushed digital and remote marketing of pharmaceutical products into high gear, according to Jamie Peck, managing director of iON.

To read all of these articles and more, visit centerforbiosimilars.com.